Compounds > erlotinib
Page last updated: 2024-09-05

erlotinib and mk 0752

erlotinib has been researched along with mk 0752 in 2 studies

Compound Research Comparison

Studies
(erlotinib)		Trials
(erlotinib)		Recent Studies (post-2010)
(erlotinib)		Studies
(mk 0752)		Trials
(mk 0752)		Recent Studies (post-2010) (mk 0752)
221018012011

Protein Interaction Comparison

ProteinTaxonomyerlotinib (IC50)mk 0752 (IC50)
Presenilin-1Homo sapiens (human)0.03
Presenilin-2Homo sapiens (human)0.03
Gamma-secretase subunit APH-1BHomo sapiens (human)0.03
NicastrinHomo sapiens (human)0.03
Gamma-secretase subunit APH-1AHomo sapiens (human)0.03
Gamma-secretase subunit PEN-2Homo sapiens (human)0.03

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1

Other Studies

2 other study(ies) available for erlotinib and mk 0752

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023